FBDD Fragments Base Drugs Discovery | Design
   
               
Search    
2-Apr-2014
  IOTA Pharmaceuticals in 7.8M consortium tackling neglected parasitic diseases
   
21-Sep-2012
  IOTA InFarmatik Press Release
   
22-Feb-2011
  IOTA announces KINOMED, a new partnership to accelerate protein kinase drug discovery Cambridge, UK / Odense, Denmark / Lund, Sweden, February 22, 2011
   
17-Aug-2009
  New consortium to develop drugs for neglected tropical diseases
   
23-Apr-2008
  IOTA announces SPR initiative with Beactica AB
   
21-Dec-2007
  IOTA announces FBDD screening services
   
21-Dec-2007
  IOTA announces collaboration with Vitas M-laboratory and new FBDD library:IOTA-Vitas 4000
   
5-Aug-2007
  IOTA Pharmaceuticals established; research centers in the UK, the Netherlands, and India.
   
3-Aug-2007
  IOTA announces FBDD Initiative with the VU University, Amsterdam
   
25-Sep-2007
  IOTA announces first FBDD product: IOTA Diverse 1500
   
 
 
We have created IOTA specifically to serve researchers in the emerging area of fragment-based drug discovery. This field, covering as it does both structure-based drug design, high-content drug screening and structure-guided, property-based lead optimization, is one of the most important and exciting areas in drug discovery today.

IOTA is collaborating with The Drug Design Resource to provide researchers with regularly updated resources in the field of fragment-based drug discovery. Welcome to the world of fragment-based drug discovery!
 
FRAGMENT-BASED DRUG DESIGN: WHY IT'S SO IMPORTANT
 
Within the space of only a few years, fragment-based drug design (FBDD) has emerged as an efficient and productive route for de novo drug discovery. In this overview of the FBDD approach IOTA co-founders David Bailey, Susan Boyd, Paul England and Iwan de Esch, review FBDD and its role in design-led discovery biology.
 
FRAGMENT-BASED DRUG DESIGN: THE LITERATURE  
 
In partnership with the Drug Design Resource, IOTA is assembling a comprehensive FBDD literature review as a service to scientists working in the FBDD area. An updated version of this literature review can be found here.
 
If you have published a paper in the FBDD area which should be included in this list and does not currently appear, please send an email to david.bailey@iotapharma.com and we will include it.
 
 
FRAGMENT-BASED DRUG DESIGN: MOLECULAR TARGETS
 
A growing number of proteins have been published as targets for FBDD studies. An updated list can be found here.
 
If you have published a paper in the FBDD area on a target which should be included in this list and does not currently appear, please send an email to david.bailey@iotapharma.com and we will include it.
 
FRAGMENT-BASED DRUG DESIGN: THE PLAYERS 
 
A growing number of companies and academic centers are using and commercialising FBDD approaches. An updated list can be found here.
 
If you are a player in the FBDD area and wish to be included in this list, please send an email to david.bailey@iotapharma.com.
 
Copyright 2007 IOTA Pharmaceuticals  |   Site by Dots & Coms